Prognosis and molecular features of malignant tumors in adults
Official title: Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis
Run by Nanfang Hospital, Southern Medical University · NCT07622667 · Data updated 2026-11-12
This study tests how key molecular features relate to outcomes in adults with malignant tumors treated at a single hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | May 29, 2026 |
| Main results expected | January 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | June 3, 2026 |
| Trial ID | NCT07622667 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histologically confirmed malignant tumors treated at Nanfang Hospital between 2017 and 2025 who can provide consent and have available tissue or blood samples for analyses.
✕Probably not a fit
Patients without available biospecimens or who do not have actionable molecular findings may not experience direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center observational study that integrates multidimensional clinical data with multi-omics information to explore factors that influence prognosis in malignant tumors. Researchers will collect electronic medical record data and tumor tissue or blood samples from consenting adults treated between 2017 and 2025, performing sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry. The goal is to help build prognostic models, identify potential therapeutic targets, and optimize treatment strategies. Data will come from routine care and biobanked specimens to examine associations between molecular profiles and survival outcomes.
Why it matters
Potential benefit: If successful, the study could improve prognostic prediction and guide personalized treatment decisions for patients with malignant tumors.
How similar studies have gone: Previous observational work using integrated clinical and multi-omics data has yielded valuable prognostic insights, though results may vary by tumor type.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form. 2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. 4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry. Exclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.
Where it's running
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Wei Wang Wang
- Email: 29262574@qq.com
- Phone: 02061642135
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-FL-031 PET for diagnosing and staging cancer
This project will test whether 68Ga-FL-031 PET imaging, compared with 18F-FDG PET, can detect and stage small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumors in adults.
-
LM-350 treatment for advanced solid tumors
This trial will test LM-350, an experimental injectable drug, in adults with advanced solid tumors who have not responded to or cannot receive standard treatments.
-
mRNA vaccine targeting KRAS-mutated cancers
We will try an mRNA vaccine that targets KRAS mutations in adults with KRAS-mutated solid tumors, given alone or with the immunotherapy drug toripalimab and/or standard chemotherapy.
-
Testing SSS59 for advanced malignant tumors
This study is testing a new treatment called SSS59 to see if it is safe and effective for people with advanced cancer.
-
Testing LM-299 for advanced malignant tumors
This study is testing a new treatment called LM-299 to see if it is safe and can help people with advanced solid tumors that haven't responded to other therapies.
-
Testing LM-101 Injection for Advanced Malignant Tumors
This study is testing a new injection called LM-101 to see if it is safe and effective for people with advanced malignant tumors, both on its own and with other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.